血GFAP和粉样蛋白病理学预测了MCI中多域干预的认知反应
Myung-Hoon Han1, Mina Hwang2, Hyuk Sung Kwon2
1Department of Neurosurgery, Hanyang University Guri Hospital, Guri 11923, Republic of Korea.
Aging and disease
|July 18, 2025
概括
血质纤维酸蛋白 (GFAP) 可以预测对轻度认知障碍 (MCI) 干预的认知反应. 较高的GFAP水平,特别是粉样蛋白阳性,与MCI患者的认知改善较低相关.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 老年医学 老年医学
背景情况:
- 轻度认知障碍 (MCI) 在老年人群中构成了重大挑战.
- 预测MCI的干预效果对于个性化治疗至关重要.
- 粉样蛋白病理是认知衰退的关键因素,但预测生物标志物是有限的.
研究的目的:
- 研究质纤维酸性质蛋白 (GFAP) 作为MCI中多域干预的认知反应的预测生物标志物.
- 基于粉样β斑块沉积的GFAP预测值的分层.
- 评估GFAP水平与老年MCI患者的认知变化之间的关联.
主要方法:
- 一项为期24周的多中心随机对照试验 (RCT),涉及300名老年MCI参与者 (SUPERBRAIN-MEET).
- 氨基酸状况通过血酸化的tau 181切断值来确定.
- 多变量线性回归分析了GFAP水平与重复电池对神经心理状况评估 (RBANS) 评分的变化,按粉样蛋白状况和干预分层.
主要成果:
- 较高的基线和6个月的血GFAP水平与6个月的较小认知改善 (RBANS得分) 有关.
- 在接受多领域干预的粉素阳性参与者中,更高的基线GFAP与显著减少的认知改善相关 (β = -8.661,p = 0.040).
- 这些发现是在后 hoc 探索性子分析中观察到的.
结论:
- 血GFAP可以作为预测生物标志物,用于MCI老年患者对多领域干预的认知反应.
- 基线GFAP水平,特别是在可能患有粉样蛋白病理的个体中,可以帮助预测治疗结果.
- GFAP可能表明MCI的早期认知阶段过渡.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.1K
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
